KUALA LUMPUR (Nov 10): Technology group Omesti Bhd said on Wednesday that it has increased its investment in the Bemed Group of companies with the acquisition of a 70% shareholding in each of nine other Bemed pharmaceutical businesses, and the investment represents a total cash consideration of RM15.8 million. Earlier this year, Omesti acquired a 70% shareholding in licensed healthcare provider Bemed Tempua Sdn Bhd, which holds a master sales and distribution agreement for the Sinovac Covid-19 vaccine with Pharmaniaga LifeScience Sdn Bhd. The Bemed companies that form part of the group’s latest acquisition are engaged in various activities, including trading and retail sale of pharmaceutical products, orthopaedic and medical goods, perfumery products, cosmetics and toiletries. Omesti executive director Gerard Monteiro said in a statement that the additional investment in the Bemed Group will enable Omesti to further expand its portfolio of healthcare services and its customer base. Omesti shares closed one sen or 2.38% lower at 41 sen on Wednesday, valuing the group at RM224.08 million.

Source: The Edge Markets November 10, 2021 21:57 UTC